Integrin-linked kinase cytoplasmic and nuclear expression in laryngeal carcinomas
Integrin-linked kinase cytoplasmic and nuclear expression in laryngeal carcinomas
复制标题
DOI：
10.1007/s00428-008-0668-8
复制
发表时间：
2008-11-01
期刊：
影响因子：
3.5
通讯作者：
Papadaki, Helen
中科院分区：
文献类型：
--
作者：
Goulioumis, Anastasios K.;Bravou, Vasiliki;Papadaki, Helen
整合素连接激酶（ILK）与几种人类恶性肿瘤的发生和进展有关。先前的体外研究也表明ILK参与Akt和β -catenin的激活以及E-cadherin表达的调节。然而，ILK在人类喉癌中的作用及其在该疾病中可能的体内下游效应物目前尚不清楚。通过免疫组化检测97例浸润性喉癌组织中ILK、磷酸化akt （p-Akt）、E-cadherin和β -catenin的蛋白表达。细胞质和细胞核中ILK和p-Akt表达增加，E-cadherin膜表达减少，细胞核中β -catenin积聚，分别占87.6%、85.6%、71.1%和43.3%。我们的研究结果表明，ILK的表达可能与人类喉癌有关，其在细胞核中的定位可能提出了该分子的新核功能。此外，ILK表达的增强与Akt的激活相关，而与E-cadherin的下调和β -catenin的激活无关。最后，在我们的材料中，虽然活化的Akt似乎是分化良好的肿瘤的特征，但E-cadherin的缺失和β -catenin的活化与高级别癌相关。
Integrin-linked kinase (ILK) has been implicated in the development and progression of several human malignancies. Previous in vitro studies also implicate ILK in the activation of Akt and beta-catenin as well as in the regulation of E-cadherin expression. However, the role of ILK in human laryngeal cancer and its possible in vivo downstream effectors in the disease are currently unknown. We examined by immunohistochemistry the protein expression of ILK, phosphorylated-Akt (p-Akt), E-cadherin, and beta-catenin in 97 invasive squamous laryngeal carcinomas. Increased cytoplasmic and nuclear expression of ILK and p-Akt decreased membranous expression of E-cadherin and nuclear accumulation of beta-catenin was found in 87.6%, 85.6%, 71.1%, and 43.3% of cases, respectively. Our results suggest that ILK expression may be implicated in human laryngeal carcinoma and its localization in the nucleus possibly proposes novel nuclear functions of this molecule. In addition, enhanced ILK expression correlates with activation of Akt but not with downregulation of E-cadherin and activation of beta-catenin. Finally, in our material while activated Akt seems to characterize well-differentiated tumors, loss of E-cadherin and activation of beta-catenin correlated with high grade carcinomas.